{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:47:23Z","timestamp":1761648443174,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.aohep.2020.09.002","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T01:39:05Z","timestamp":1600306745000},"page":"100257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy and safety of glecaprevir\/pibrentasvir in treatment-na\u00efve adults with chronic hepatitis C virus genotypes 1\u20136 in Brazil"],"prefix":"10.1016","volume":"20","author":[{"given":"Mario","family":"Periba\u00f1ez-Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Cheinquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lino","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Patelli","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio Reis","family":"\u00c1lvares-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Madruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edison Roberto","family":"Parise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio Guimar\u00e3es","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juvencio","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Villanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adalgisa","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Mazzoleni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ecio","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Faria","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Fredrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2017","series-title":"Global Hepatitis Report","author":"World Health Organization","key":"10.1016\/j.aohep.2020.09.002_bib0005"},{"key":"10.1016\/j.aohep.2020.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1186\/s12889-016-3784-4","article-title":"The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy","volume":"16","author":"Mesquita","year":"2016","journal-title":"BMC Public Health"},{"key":"10.1016\/j.aohep.2020.09.002_bib0015","unstructured":"World Hepatitis Alliance. Sao Paulo Community Declaration on Hepatitis World Health Summit. Available at: https:\/\/www.who.int\/hepatitis\/news-events\/sao_paulo_community_declaration_on_hepatitis.pdf?ua=1. [Accessed December 2019]."},{"key":"10.1016\/j.aohep.2020.09.002_bib0020","unstructured":"World Health Organization. Progress Report on Access to Hepatitis C Treatment. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260445\/WHO-CDS-HIV-18.4-eng.pdf;jsessionid=A752ADD1C6C1BEC9D586B19EEF4912B1?sequence=1. [Accessed December 2019]."},{"key":"10.1016\/j.aohep.2020.09.002_bib0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bjid.2019.04.010","article-title":"Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach","volume":"23","author":"Benzaken","year":"2019","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.aohep.2020.09.002_bib0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bjid.2015.04.004","article-title":"Disease burden of chronic hepatitis C in Brazil","volume":"19","author":"Ferreira","year":"2015","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.aohep.2020.09.002_bib0035","unstructured":"AbbVie. Mavyret US. Available at: https:\/\/www.rxabbvie.com\/pdf\/mavyret_pi.pdf. [Accessed December 2019]."},{"year":"2019","series-title":"Maviret (Glecaprevir\/Pibrentasvir) 2019 application for inclusion on WHO model list of essential medicines","author":"AbbVie","key":"10.1016\/j.aohep.2020.09.002_bib0040"},{"key":"10.1016\/j.aohep.2020.09.002_bib0045","unstructured":"AbbVie. Maviret Brazil. Available at: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/25351467396201779\/?nomeProduto=Maviret. [Accessed January 2020]."},{"key":"10.1016\/j.aohep.2020.09.002_bib0050","unstructured":"European Medicines Agency. Maviret EU. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf. [Accessed March 2020]."},{"key":"10.1016\/j.aohep.2020.09.002_bib0055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.09.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01249-18","article-title":"Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.aohep.2020.09.002_bib0065","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.aohep.2020.09.002_bib0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.09.002_bib0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.09.002_bib0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bjid.2018.06.004","article-title":"Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil","volume":"22","author":"Holzmann","year":"2018","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.aohep.2020.09.002_bib0085","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bjid.2018.04.003","article-title":"Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil","volume":"22","author":"Ferreira","year":"2018","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.aohep.2020.09.002_bib0090","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s12325-019-01012-6","article-title":"Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections","volume":"36","author":"Welzel","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.aohep.2020.09.002_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227082","article-title":"HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: a survey representative of an entire country","volume":"15","author":"Nutini","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2020.09.002_bib0100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1186\/s12879-017-2820-z","article-title":"Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review","volume":"17","author":"Fathi","year":"2017","journal-title":"BMC Infect Dis"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268120301721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268120301721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:40:48Z","timestamp":1761648048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268120301721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":20,"alternative-id":["S1665268120301721"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2020.09.002","relation":{},"ISSN":["1665-2681"],"issn-type":[{"type":"print","value":"1665-2681"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of glecaprevir\/pibrentasvir in treatment-na\u00efve adults with chronic hepatitis C virus genotypes 1\u20136 in Brazil","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2020.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C.","name":"copyright","label":"Copyright"}],"article-number":"100257"}}